Fort Worth-based Nacuity Pharmaceuticals has expanded its business advisory board with the appointment of Daniel Feller.
Nacuity is a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative stress.
“Daniel and his family are a pillar of the rare genetic disease community in Australia and we’re honored to welcome him to our advisory team,” Halden Conner, chairman, CEO and co-founder of Nacuity Pharmaceuticals, said in a statement. “We look forward to leveraging his unique perspective and experience as an Usher syndrome caregiver, as well as his business-building acumen, as we advance our clinical programs aimed to stop oxidative tissue damage, a largely unaddressed disease mechanism in conditions including retinitis pigmentosa associated with Usher syndrome.”
Usher syndrome is a rare genetic disease that affects both hearing and vision. It causes deafness or hearing loss and the eye disease of retinitis pigmentosa.
Feller founded Talisman Licensing, a brand building agency in Melbourne, Australia, and has served as its CEO since its founding in 2007.
He also is chief operations officer at GEM42S Ltd, a pioneering biotechnology company dedicated to the development of cutting-edge therapies using Base Editing and CRISPR techniques to treat rare diseases and advance towards addressing major diseases.
Nacuity said that GEM42S was founded on the principle of leveraging innovative genomic technologies and is committed to revolutionizing the landscape of medicine by targeting the root causes of genetic disorders.
After their son was born afflicted with Usher syndrome 1F, Feller and his wife, Hollie Feller, co-founded Genetic Cures Australia to support the growth of medical research on gene-based approaches and emerging therapies for inherited rare diseases in Australia.
Hollie Feller also co-founded and currently serves as the director of UsherKids Australia, an Australian-based support network for families with children diagnosed with Usher syndrome.
“I know firsthand the importance of the work underway to improve the lives of people with Usher syndrome like my son, and am deeply committed to accelerating promising research toward treatments and cures for genetic conditions like Usher syndrome,” Daniel Feller said. “Nacuity’s oxidative stress therapies have broad potential to treat a variety of diseases, including retinitis pigmentosa associated with Usher syndrome. I look forward to working with Nacuity at this pivotal stage as the Company advances its clinical programs to make a difference for people living with ocular diseases.”
Feller joins existing Nacuity advisory board member Scott Dorfman, co-founder, chairman and CEO of Odylia Therapeutics, a nonprofit biotechnology company focused on the development of treatments for people living with rare diseases, and founder and former chairman and CEO of Innotrac Corp.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure. “I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement. “Secretome Therapeutics’ team, vision, and groundbreaking products have the potential to revolutionize treatment for a wide range of chronic, inflammatory diseases, and I am thrilled to…
-
Arjun Malhotra has been a prominent figure in the Indian IT entrepreneurial scene and is widely known for his instrumental role in co-founding the HCL Group in 1975.
-
"Since data is crucial for maintaining ongoing DEIB initiatives and dedication, Kanarys leads the way in establishing quantifiable DEIB strategies, thanks to its data-centric methodology aimed at creating a fairer future for all work settings," says Google CDO and Kanary's Board Member Melonie Parker.
-
Embark said its five new board appointments reinforce its commitment to deliver value and experience across the organization and will complement the existing executive team.
-
The committee will provide a "crucial public body" for the discussion, development, and dissemination of plans related to Colossal's planned "de-extinction" and rewilding of the Tasmanian tiger—a slim, striped keystone species that was native to Australia, Tasmania, and New Guinea before being hunted to extinction some 100 years ago.
